Key result
Aspirin altered eoxPL generation in ASCVD patients and healthy subjects, lowering COX-derived eoxPL but elevating 12-LOX-diacyl forms, with LPCAT3 identified as the responsible acyltransferase.
Why the study?
The generation of prothrombotic enzymatically oxygenated phospholipids in arterial disease, their modulation by cardiovascular therapies, and the Lands cycle acyl-transferases catalyzing their formation were unknown.
How do aspirin and LPCAT3 modulate the generation of procoagulant enzymatically oxygenated phospholipids in cardiovascular disease?
Observational
How do aspirin and LPCAT3 modulate the generation of procoagulant enzymatically oxygenated phospholipids in cardiovascular disease?
Aspirin alters the procoagulant phospholipid composition of blood cells in humans at risk of thrombosis, with LPCAT3 identified as the acyltransferase generating aspirin-sensitive 12-LOX diacyl forms.
Answers are grounded in this paper and cite their sources.
Aspirin suppresses prothrombotic eoxPL in ASCVD; confirms clinical modulation and identifies LPCAT3 as regulator for future targeting.
Enzymatically oxygenated phospholipids (eoxPL) from lipoxygenases (LOX) or cyclooxygenase (COX) are prothrombotic. Their generation in arterial disease, and their modulation by cardiovascular therapies is unknown. Furthermore, the Lands cycle acyl-transferases that catalyze their formation are unidentified. eoxPL were measured in platelets and leukocytes from an atherosclerotic cardiovascular disease (ASCVD) cohort and retrieved human arterial thrombi from three anatomical sites. The impact of age, gender, and aspirin was characterized in platelets from healthy subjects administered low-dose aspirin. The role of lysophosphatidylcholine acyltransferase 3 (LPCAT3) in eoxPL biosynthesis was tested using an inhibitor and a cell-free assay. Platelets from ASCVD patients generated lower levels of COX-derived eoxPL but elevated 12-LOX-diacyl forms, than platelets from healthy controls. This associated with aspirin and was recapitulated in healthy subjects by aspirin supplementation. P2Y12 inhibition had no impact on eoxPL. LPCAT3 inhibition selectively prevented 12-LOX-derived diacyl-eoxPL generation. LPCAT3 activity was not directly altered by aspirin. P2Y12 inhibition or aspirin had little impact on eoxPL in leukocytes. Complex aspirin-dependent gender and seasonal effects on platelet eoxPL generation were seen in healthy subjects. Limb or coronary (ST-elevation myocardial infarction, STEMI) thrombi displayed a platelet eoxPL signature while carotid thrombi had a white cell profile. EoxPL are altered in ASCVD by a commonly used cardiovascular therapy, and LPCAT3 was identified as the acyltransferase generating aspirin-sensitive 12-LOX diacyl forms. These changes to the phospholipid composition of blood cells in humans at risk of thrombosis may be clinically significant where the procoagulant membrane plays a central role in driving elevated thrombotic risk.
No takes yet. Share an insight, caveat, or question.
Protty et al. (2024) conducted an observational in Atherosclerotic cardiovascular disease (ASCVD). Aspirin vs. Healthy controls was evaluated on eoxPL generation. Aspirin altered eoxPL generation in ASCVD patients and healthy subjects, lowering COX-derived eoxPL but elevating 12-LOX-diacyl forms, with LPCAT3 identified as the responsible acyltransferase.
Synapse has enriched 10 related papers. Consider them for comparative context: